WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology

SHANGHAI, July 23 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc.(NYSE: WX), a leading pharmaceutical, biotechnology, and medical deviceresearch and development outsourcing company with operations in China and theUnited States, today announced that Dr. Chi-Chung Chan has been appointed asVice President of Pharmacology. He will report directly to Dr. Shuhui Chen,Chief Scientific Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Dr. Chi-Chung Chan worked at Merck & Co. for 26years in scientific positions of increasing responsibility. At Merck, he ledpharmacology research efforts in inflammation and pain, allergic diseases,cardiovascular diseases, respiratory diseases and, most recently, diabetes andobesity. Dr. Chan obtained a Ph.D. in Pharmacology from the University ofOttawa and a B.S. degree in Biology from Chinese University of Hong Kong.

"I am pleased to welcome Chi-Chung on board as we continue to develop ourdrug discovery capabilities in pharmacology," said Dr. Ge Li, Chairman andChief Executive Officer. "WuXi is committed to building a world-classscientific management team with extensive experience in a broad range ofscientific disciplines to meet the needs of our customers."For more information, please contact: Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: [email protected] Stephanie Liu (for the media) Associate Director of Corporate Communications Department Tel: +86-21-5046-4362 Email: [email protected] Web: http://www.wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...